·	Application No.	Applicant(s)
Notice of Allowability	10/616,511	MISSELWITZ ET AL.
	Examiner	Art Unit
	D. L. Jones	1618
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 8/24/07 and 9/28/07.		
2. A The allowed claim(s) is/are 1-50.		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
'4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		·
Attachment(s)		•
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 	7. 🛭 Examiner's Amendr	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	ent of Reasons for Allowance
-	9.	

Page 2

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 8/24/07 wherein the specification was amended and claims 8, 9, 11, 14-17, 19, 21, 25, 27, 29, 30, 37, 40, and 50 were amended.

Note: Claims 1-50 are pending.

EXAMINER'S AMENDMENT

2. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Csaba Henter on 9/28/07.

The application has been amended as follows.

In claim 50, line 31, delete -or-.

In claim 50, line 29, insert -or- after the structure.

Replace claim 26 with the following.

Claim 26 (Currently Amended): A method according to claim 22, wherein in the compounds of general formula lb, L1 means one of the following

Application/Control Number: 10/616,511 Page 3

Art Unit: 1618

COMMENTS/NOTES

3. The claims are allowable over the prior art of record for reasons of record in the office action mailed 6/1/07.

- 4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

Art Unit: 1618

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

D. L. Jones

Primary Examiner
Art Unit 1618

September 28, 2007

α-(CH₂)₈-β α -CH₂-CH₂-(O-CH₂-CH₂-)y- β α -CH₂-(O-CH₂-CH₂- λ_V - β , α-CH2-NH-CO-β α-CH2-CH2-NH-SO2-B α-CH2-NH-CO-CH2-N(CH2COOH)-SO2-β α-CH2-NH-CO-CH2-N(C2H5)-SO2-β α -CH₂-NH-CO-CH₂-N(C₁₀H₂₁)-SO₂- β α-CH2-NH-CO-CH2-N(C6H13)-SO2-β α-CH₂-NH-CO-(CH₂)₁₀-N(C₂H₅)-SO₂-β α-CH2-NH-CO-CH2-N(-CH2-C6H5)-SO2-β α-CH2-NH-CO-CH2-N(-CH2-CH2-OH)SO2-β α-CH2-NHCO-(CH2)10-S-CH2CH2-β α-CH2NHCOCH2-O-CH2CH2-β α-CH2-CH2NHCOCH2-O-CH2CH2-β α-CH2-(CH2-CH2-O);-(CH2)3NHCO-CH2-O-CH2CH2-β α-CH2NHCO(CH2)10-O-CH2CH2-β α-CH2CH2NHCO(CH2)10-O-CH2CH2-β

 $\begin{array}{l} \alpha\text{-CH}_2\text{-O-CH}_2\text{-C}(\text{CH}_2\text{-OCH}_2\text{CH}_2\text{-C}6\text{F}_{13})_2\text{-CH}_2\text{-OCH}_2\text{-CH}_2\text{-B} \\ \alpha\text{-CH}_2\text{-NHCOCH}_2\text{CH}_2\text{CON-CH}_2\text{CH}_2\text{NHCOCH}_2\text{N}(\text{C}_2\text{H}_5)\text{SO}_2\text{C}8\text{F}_{17}\beta \\ \alpha\text{-CH}_2\text{-CH}_2\text{NHCOCH}_2\text{N}(\text{C}_2\text{H}_6)\text{-SO}_2\text{-}\beta \\ \alpha\text{-CH}_2\text{-O-CH}_2\text{-CH}(\text{OC}_{10}\text{H}_{21})\text{-CH}_2\text{-O-CH}_2\text{CH}_2\text{-}\beta \\ \alpha\text{-(CH}_2\text{NHCO})_4\text{-CH}_2\text{O-CH}_2\text{CH}_2\text{-}\beta \\ \alpha\text{-(CH}_2\text{NHCO})_3\text{-CH}_2\text{O-CH}_2\text{CH}_2\text{-}\beta \\ \alpha\text{-CH}_2\text{-OCH}_2\text{C}(\text{CH}_2\text{OH})_2\text{-CH}_2\text{-O-CH}_2\text{CH}_2\text{-}\beta \end{array}$

α-CH2NHCOCH2N(C6H5)-SO2-β α-NHCO-CH2-CH2-β α-NHCO-CH2-O-CH2CH2-B α-NH-CO-B α-NH-CO-CH2-N(CH2COOH)-SO2-β α-NH-CO-CH2-N(C2H5)-SO2-β α-NH-CO-CH2-N(C10H21)-SO2-B α-NH-CO-CH₂-N(C₆H₁₃)-\$O₂-β α-NH-CO-(CH₂)10-N(C₂H₅)-SO₂-β α-NH-CO-CH₂-N(-CH₂-C₆H₅)-SO₂-β α-NH-CO-CH₂-N(-CH₂-CH₂-OH)SO₂-β α-NH-CO-CH₂-β α-CH2-O-C6H4-O-CH2-CH2-B α-CH2-C6H4-O-CH2-CH2-β α-N(C2H5)-SO2-β α-N(C6H5)-SO2-β α-N(C10H21)-SO2-β a-N(C6H13)-SO2-B α -N(C₂H₄OH)-SO₂- β α-N(CH2COOH)-SO2-B α-N(CH2C6H5)-SO2-β -N-[CH(CH2OH)2]-SO2-β α-N-[CH(CH2OH)CH(OH)(CH2OH)]-SO2-β

wherein

or

stands for integers 1 to 15 and

y stands for integers 1 to 6.